Clinical Trial

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, pharmacokinetic, pharmacodynamic and efficacy of APG-2575 single agent and in combination with other therapeutic agents in patients with relapsed/refractory CLL/SLL.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-07-30; most recent amendment 2025-04-15.
Status change: Not Yet Recruiting → Recruiting 2020-10-14
Trial Details
NCT Number NCT04494503
Lead Sponsor Ascentage Pharma Group Inc.
Conditions Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Enrollment 123 participants
Start Date 2020-08-31
Primary Completion 2024-10-20 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-04-16